Please provide your email address to receive an email when new articles are posted on . Sunovion recently announced positive phase 3 study findings for Latuda for bipolar I disorder depression in ...

Sunovion Pharmaceuticals Inc., a Marlborough based drug company now owned by Dainippon Sumitomo Pharma Co. Ltd. of Japan, said that it has received regulatory approval to market its Latuda drug for ...

Dainippon Sumitomo Pharma announced results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of Latuda (lurasidone; Sunovion) as adjunctive therapy and monotherapy, ...

Latuda's (lurasidone HCI; Sunovion) expanded indication has been approved for pediatric patients aged 10 to 17 years who have major depressive episodes associated with bipolar I disorder. The Food and ...

Latuda, a new bipolar anti-depression brand from Sunovion, has joined the DTC fray with an integrated campaign targeted at women betweeen 25 and 49. This is a very complicated disease to ...

Please provide your email address to receive an email when new articles are posted on . Latuda use was associated with statistically significant improvements on individual quality-of-life items ...

The U.S. Food and Drug Administration (FDA) approved a new treatment for bipolar depression this month. The drug comes from Marlborough-based Sunovion Pharmaceuticals, which can now distribute Latuda ...

Sunovion Pharmaceuticals Inc. of Marlborough, Mass. has received the go-ahead to market its already-approved drug for schizophrenia as a potential treatment for patients with bipolar depression.

Treating bipolar depression with standard antidepressants has long been controversial, because some patients do not respond and it is believed that the drugs trigger manic episodes. Two physicians ...

Healthcare company Wellesta Buergli and pharmaceutical firm Sumitomo Pharma have launched lurasidone, an innovative antipsychotic drug, in the Philippines. Lurasidone, marketed under the brand name ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) today announced data presentations on the late-stage pipeline candidate SEP-363856, a trace amine-associated receptor 1 ...